<p>Gladstone Institutional Advisory LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中表示，在第三季度將其在賽默飛世爾（Thermo Fisher Scientific Inc.，NYSE:TMO - 免費報告）的持股減少了 32.1%。該公司在此期間出售了 1,921 股後，持有 4,069 股醫療研究公司的股票。截至其最近的 SEC 文件，Gladstone Institutional Advisory LLC 在賽默飛世爾的持股價值為 1,974,000 美元。</p>
<ul>
<li>行業輪動：2026 年的兩項聰明資金舉措</li>
</ul>
<p>其他幾家對沖基金和機構投資者也對其在該公司的持倉進行了調整。CBIZ Investment Advisory Services LLC 在第一季度將其在賽默飛世爾的持股增加了 137.5%。CBIZ Investment Advisory Services LLC 目前持有 57 股醫療研究公司的股票，價值 28,000 美元，此前在上個季度又購買了 33 股。Highline Wealth Partners LLC 在第三季度將其在賽默飛世爾的持倉增加了 126.9%。Highline Wealth Partners LLC 目前持有 59 股醫療研究公司的股票，價值 29,000 美元，此前在此期間又獲得了 33 股。Anderson Financial Strategies LLC 在第一季度購買了賽默飛世爾的新頭寸，價值 30,000 美元。Capital A Wealth Management LLC 在第二季度將其在賽默飛世爾的持股增加了 825.0%。Capital A Wealth Management LLC 目前持有 74 股醫療研究公司的股票，價值 30,000 美元，此前在上個季度又購買了 66 股。最後，DiNuzzo Private Wealth Inc. 在第二季度將其在賽默飛世爾的持股增加了 406.7%。DiNuzzo Private Wealth Inc. 目前持有 76 股醫療研究公司的股票，價值 31,000 美元，此前在此期間又購買了 61 股。對沖基金和其他機構投資者持有該公司 89.23% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些股票分析師最近對 TMO 股票發表了評論。Redburn Partners 在 10 月 8 日的研究報告中將賽默飛世爾的目標價設定為 580.00 美元。滙豐全球研究在 12 月 1 日的報告中將賽默飛世爾的評級從 “持有” 上調至 “強力買入”。Evercore ISI 在週一重申了 “跑贏大盤” 的評級，並對賽默飛世爾的股票發佈了 650.00 美元的目標價。Cowen 在週三的研究報告中重申了對賽默飛世爾股票的 “買入” 評級。最後，Wall Street Zen 在 10 月 25 日的報告中將賽默飛世爾的評級從 “持有” 上調至 “買入”。一位股票研究分析師給予該股票 “強力買入” 評級，二十位給予 “買入” 評級，三位給予 “持有” 評級。根據 MarketBeat.com 的數據，賽默飛世爾目前的平均評級為 “適度買入”，共識目標價為 621.70 美元。</p>
<ul>
<li>機構看好這三家公司，你也應該關注嗎？</li>
</ul>
<p><strong>獲取我們最新的 TMO 股票分析</strong></p>
<h2>賽默飛世爾股價下跌 0.6%</h2>
<p>週四，NYSE TMO 開盤價為 616.97 美元。該公司的 50 日移動平均價格為 579.34 美元，200 日移動平均價格為 514.40 美元。賽默飛世爾的 12 個月低點為 385.46 美元，12 個月高點為 628.08 美元。該公司的債務與股本比率為 0.62，流動比率為 1.50，速動比率為 1.11。該公司的市值為 2318 億美元，市盈率為 35.64，市盈增長比率為 4.08，貝塔值為 0.91。</p>
<ul>
<li>這三隻股票通過回購傳遞市場信心</li>
</ul>
<p>賽默飛世爾（NYSE:TMO - 獲取免費報告）最近在 10 月 22 日發佈了季度財報。該醫療研究公司報告的每股收益（EPS）為 5.79 美元，超出市場共識預期的 5.50 美元，超出幅度為 0.29 美元。賽默飛世爾的淨利潤率為 15.02%，股本回報率為 16.97%。該公司在本季度的收入為 111.2 億美元，而市場共識預期為 109 億美元。在去年同期，該公司每股收益為 5.28 美元。賽默飛世爾本季度的收入同比增長 4.9%。賽默飛世爾已將其 2025 財年的指引設定為每股收益 22.600-22.860 美元。平均而言，賣方分析師預計賽默飛世爾將在當前財年發佈每股收益 23.28 美元。</p>
<h2>賽默飛世爾宣佈分紅</h2>
<p>該公司最近還宣佈了一項季度分紅，將於 1 月 15 日（星期四）支付。12 月 15 日（星期一）的股東將獲得每股 0.43 美元的分紅。該分紅的除息日為 12 月 15 日（星期一）。這代表着每年 1.72 美元的分紅和 0.3% 的收益率。賽默飛世爾的派息比率為 9.94%。</p>
<p>賽默飛世爾宣佈其董事會於 11 月 6 日啓動了一項股票回購計劃，授權公司回購 50 億美元的流通股。該回購授權允許該醫療研究公司通過公開市場購買最多 2.4% 的股份。股票回購計劃通常表明公司的管理層認為其股票被低估。</p>
<h2>內部買賣</h2>
<p>在其他新聞中，執行副總裁弗雷德裏克·M·洛瑞於 12 月 2 日星期二出售了 6,912 股公司的股票。股票的平均售價為 581.94 美元，總交易額為 4,022,369.28 美元。交易完成後，這位執行副總裁直接持有公司 14,367 股股票，估值約為 8,360,731.98 美元。這筆交易代表了他們持股比例的 32.48% 的減少。該出售在向 SEC 的法律文件中披露，相關信息可通過此鏈接訪問。此外，首席執行官馬克·N·卡斯帕於 10 月 27 日星期一出售了 7,250 股公司的股票。股票的平均售價為 566.10 美元，總交易額為 4,104,225.00 美元。出售完成後，首席執行官持有公司 113,762 股股票，估值約為 64,400,668.20 美元。這筆交易代表了他們持股比例的 5.99% 的減少。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士已出售 149,271 股公司股票，價值 86,507,282 美元。公司內部人士持有公司股票的 0.33%。</p>
<h2>關於賽默飛世爾</h2>
<p>（免費報告）</p>
<p>賽默飛世爾 NYSE: TMO 是全球科學儀器、試劑和耗材、軟件及服務的提供商，支持研究、臨牀和工業實驗室。該公司提供分析儀器和實驗室設備、生命科學試劑和試劑盒、專業診斷以及研究人員、臨牀醫生和製造商使用的廣泛耗材。其產品還包括實驗室信息管理和數據分析軟件，以及幫助客户高效運行復雜工作流程的服務解決方案，如儀器維護、驗證和物流。</p>
<p>賽默飛通過多個業務領域運營，廣泛涵蓋生命科學解決方案、分析儀器、專業診斷、實驗室產品和生物製藥服務，包括為製藥和生物技術公司提供的合同開發和製造服務。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過賽默飛世爾</li>
<li>你還認為白銀是個笑話？看看接下來會發生什麼。</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>崩盤前一個月</li>
<li>請勿刪除，立即閲讀</li>
<li>YDES 可能是 2026 年的生物技術突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在賽默飛世爾嗎？</h2>
<p>在考慮賽默飛世爾之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而賽默飛世爾並不在名單上。</p>
<p>雖然賽默飛世爾目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

賽默飛世爾

<p>Gladstone Institutional Advisory LLC 在第三季度減少了對賽默飛世爾（Thermo Fisher Scientific Inc.，NYSE:TMO）32.1% 的持股，目前持有 4,069 股，價值 1,974,000 美元。其他機構投資者也調整了他們的持倉。分析師為 TMO 設定的共識目標價為 621.70 美元，大多數分析師給予其 “適度買入” 的評級。該公司報告了第三季度每股收益為 5.79 美元，超出預期，營收為 111.2 億美元，同比增長 4.9%。賽默飛世爾還宣佈了季度分紅</p>

<p>Gladstone Institutional Advisory LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 32.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,069 shares of the medical research company's stock after selling 1,921 shares during the period. Gladstone Institutional Advisory LLC's holdings in Thermo Fisher Scientific were worth $1,974,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Gladstone Institutional Advisory LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中表示，在第三季度將其在賽默飛世爾（Thermo Fisher Scientific Inc.，NYSE:TMO - 免費報告）的持股減少了 32.1%。該公司在此期間出售了 1,921 股後，持有 4,069 股醫療研究公司的股票。截至其最近的 SEC 文件，Gladstone Institutional Advisory LLC 在賽默飛世爾的持股價值為 1,974,000 美元。</p>
</div><ul>
<li>Sector Rotation: 2 Smart Money Moves for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>行業輪動：2026 年的兩項聰明資金舉措</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also made changes to their positions in the business. CBIZ Investment Advisory Services LLC lifted its holdings in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares in the last quarter. Highline Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock worth $29,000 after acquiring an additional 33 shares during the period. Anderson Financial Strategies LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at $30,000. Capital A Wealth Management LLC grew its stake in Thermo Fisher Scientific by 825.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock worth $30,000 after purchasing an additional 66 shares in the last quarter. Finally, DiNuzzo Private Wealth Inc. increased its holdings in Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock worth $31,000 after purchasing an additional 61 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者也對其在該公司的持倉進行了調整。CBIZ Investment Advisory Services LLC 在第一季度將其在賽默飛世爾的持股增加了 137.5%。CBIZ Investment Advisory Services LLC 目前持有 57 股醫療研究公司的股票，價值 28,000 美元，此前在上個季度又購買了 33 股。Highline Wealth Partners LLC 在第三季度將其在賽默飛世爾的持倉增加了 126.9%。Highline Wealth Partners LLC 目前持有 59 股醫療研究公司的股票，價值 29,000 美元，此前在此期間又獲得了 33 股。Anderson Financial Strategies LLC 在第一季度購買了賽默飛世爾的新頭寸，價值 30,000 美元。Capital A Wealth Management LLC 在第二季度將其在賽默飛世爾的持股增加了 825.0%。Capital A Wealth Management LLC 目前持有 74 股醫療研究公司的股票，價值 30,000 美元，此前在上個季度又購買了 66 股。最後，DiNuzzo Private Wealth Inc. 在第二季度將其在賽默飛世爾的持股增加了 406.7%。DiNuzzo Private Wealth Inc. 目前持有 76 股醫療研究公司的股票，價值 31,000 美元，此前在此期間又購買了 61 股。對沖基金和其他機構投資者持有該公司 89.23% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of equities analysts have recently commented on TMO shares. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, October 8th. Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Monday, December 1st. Evercore ISI restated an &#34;outperform&#34; rating and issued a $650.00 price objective on shares of Thermo Fisher Scientific in a report on Monday. Cowen reaffirmed a &#34;buy&#34; rating on shares of Thermo Fisher Scientific in a research report on Wednesday. Finally, Wall Street Zen raised Thermo Fisher Scientific from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, October 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $621.70.</p>
<div class="lb-trans"><p>一些股票分析師最近對 TMO 股票發表了評論。Redburn Partners 在 10 月 8 日的研究報告中將賽默飛世爾的目標價設定為 580.00 美元。滙豐全球研究在 12 月 1 日的報告中將賽默飛世爾的評級從 “持有” 上調至 “強力買入”。Evercore ISI 在週一重申了 “跑贏大盤” 的評級，並對賽默飛世爾的股票發佈了 650.00 美元的目標價。Cowen 在週三的研究報告中重申了對賽默飛世爾股票的 “買入” 評級。最後，Wall Street Zen 在 10 月 25 日的報告中將賽默飛世爾的評級從 “持有” 上調至 “買入”。一位股票研究分析師給予該股票 “強力買入” 評級，二十位給予 “買入” 評級，三位給予 “持有” 評級。根據 MarketBeat.com 的數據，賽默飛世爾目前的平均評級為 “適度買入”，共識目標價為 621.70 美元。</p>
</div><ul>
<li>Institutions Love These 3 Companies, Should You As Well?</li>
</ul>
<div class="lb-trans"><ul>
<li>機構看好這三家公司，你也應該關注嗎？</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on TMO</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 TMO 股票分析</strong></p>
</div><h2>Thermo Fisher Scientific Trading Down 0.6%</h2>
<div class="lb-trans"><h2>賽默飛世爾股價下跌 0.6%</h2>
</div><p>NYSE TMO opened at $616.97 on Thursday. The firm's fifty day moving average price is $579.34 and its 200 day moving average price is $514.40. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $628.08. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company has a market capitalization of $231.80 billion, a price-to-earnings ratio of 35.64, a price-to-earnings-growth ratio of 4.08 and a beta of 0.91.</p>
<div class="lb-trans"><p>週四，NYSE TMO 開盤價為 616.97 美元。該公司的 50 日移動平均價格為 579.34 美元，200 日移動平均價格為 514.40 美元。賽默飛世爾的 12 個月低點為 385.46 美元，12 個月高點為 628.08 美元。該公司的債務與股本比率為 0.62，流動比率為 1.50，速動比率為 1.11。該公司的市值為 2318 億美元，市盈率為 35.64，市盈增長比率為 4.08，貝塔值為 0.91。</p>
</div><ul>
<li>These 3 Stocks Are Using Buybacks to Signal Market Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>這三隻股票通過回購傳遞市場信心</li>
</ul>
</div><p>Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter in the prior year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>賽默飛世爾（NYSE:TMO - 獲取免費報告）最近在 10 月 22 日發佈了季度財報。該醫療研究公司報告的每股收益（EPS）為 5.79 美元，超出市場共識預期的 5.50 美元，超出幅度為 0.29 美元。賽默飛世爾的淨利潤率為 15.02%，股本回報率為 16.97%。該公司在本季度的收入為 111.2 億美元，而市場共識預期為 109 億美元。在去年同期，該公司每股收益為 5.28 美元。賽默飛世爾本季度的收入同比增長 4.9%。賽默飛世爾已將其 2025 財年的指引設定為每股收益 22.600-22.860 美元。平均而言，賣方分析師預計賽默飛世爾將在當前財年發佈每股收益 23.28 美元。</p>
</div><h2>Thermo Fisher Scientific Announces Dividend</h2>
<div class="lb-trans"><h2>賽默飛世爾宣佈分紅</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is 9.94%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，將於 1 月 15 日（星期四）支付。12 月 15 日（星期一）的股東將獲得每股 0.43 美元的分紅。該分紅的除息日為 12 月 15 日（星期一）。這代表着每年 1.72 美元的分紅和 0.3% 的收益率。賽默飛世爾的派息比率為 9.94%。</p>
</div><p>Thermo Fisher Scientific declared that its board has initiated a share buyback plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's management believes its stock is undervalued.</p>
<div class="lb-trans"><p>賽默飛世爾宣佈其董事會於 11 月 6 日啓動了一項股票回購計劃，授權公司回購 50 億美元的流通股。該回購授權允許該醫療研究公司通過公開市場購買最多 2.4% 的股份。股票回購計劃通常表明公司的管理層認為其股票被低估。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other news, EVP Frederick M. Lowery sold 6,912 shares of the firm's stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the transaction, the executive vice president directly owned 14,367 shares in the company, valued at approximately $8,360,731.98. This trade represents a 32.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 7,250 shares of the company's stock in a transaction on Monday, October 27th. The shares were sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company's stock, valued at approximately $64,400,668.20. This trade represents a 5.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 149,271 shares of company stock valued at $86,507,282 in the last 90 days. Company insiders own 0.33% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，執行副總裁弗雷德裏克·M·洛瑞於 12 月 2 日星期二出售了 6,912 股公司的股票。股票的平均售價為 581.94 美元，總交易額為 4,022,369.28 美元。交易完成後，這位執行副總裁直接持有公司 14,367 股股票，估值約為 8,360,731.98 美元。這筆交易代表了他們持股比例的 32.48% 的減少。該出售在向 SEC 的法律文件中披露，相關信息可通過此鏈接訪問。此外，首席執行官馬克·N·卡斯帕於 10 月 27 日星期一出售了 7,250 股公司的股票。股票的平均售價為 566.10 美元，總交易額為 4,104,225.00 美元。出售完成後，首席執行官持有公司 113,762 股股票，估值約為 64,400,668.20 美元。這筆交易代表了他們持股比例的 5.99% 的減少。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士已出售 149,271 股公司股票，價值 86,507,282 美元。公司內部人士持有公司股票的 0.33%。</p>
</div><h2>About Thermo Fisher Scientific</h2>
<div class="lb-trans"><h2>關於賽默飛世爾</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.</p>
<div class="lb-trans"><p>賽默飛世爾 NYSE: TMO 是全球科學儀器、試劑和耗材、軟件及服務的提供商，支持研究、臨牀和工業實驗室。該公司提供分析儀器和實驗室設備、生命科學試劑和試劑盒、專業診斷以及研究人員、臨牀醫生和製造商使用的廣泛耗材。其產品還包括實驗室信息管理和數據分析軟件，以及幫助客户高效運行復雜工作流程的服務解決方案，如儀器維護、驗證和物流。</p>
</div><p>Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.</p>
<div class="lb-trans"><p>賽默飛通過多個業務領域運營，廣泛涵蓋生命科學解決方案、分析儀器、專業診斷、實驗室產品和生物製藥服務，包括為製藥和生物技術公司提供的合同開發和製造服務。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Thermo Fisher Scientific</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>A month before the crash</li>
<li>Do not delete, read immediately</li>
<li>YDES Could Be 2026's Biotech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過賽默飛世爾</li>
<li>你還認為白銀是個笑話？看看接下來會發生什麼。</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>崩盤前一個月</li>
<li>請勿刪除，立即閲讀</li>
<li>YDES 可能是 2026 年的生物技術突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TMO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Thermo Fisher Scientific Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在賽默飛世爾嗎？</h2>
</div><p>Before you consider Thermo Fisher Scientific, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮賽默飛世爾之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而賽默飛世爾並不在名單上。</p>
</div><p>While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然賽默飛世爾目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Gladstone Institutional Advisory LLC 減少了其在賽默飛世爾公司的股票持有量 $TMO